Yarrow Bioscience (YARW) Payables (2016 - 2026)

Yarrow Bioscience (YARW) has reported Payables for 11 consecutive years, with $614000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Payables fell 56.58% year-over-year to $614000.0; the trailing twelve-month figure through Jun 2026 stood at $614000.0 (down 56.58% YoY), and the FY2025 full-year result was $1.0 million, down 61.54% from the prior year.
• Payables improved to $614000.0 in Q2 2026 per YARW's latest filing, from $261000.0 in the prior quarter.
• Across five years, Payables topped out at $4.5 million in Q2 2024 and bottomed at $261000.0 in Q1 2026.
• Historically, Payables has averaged $2.2 million across 5 years, with a median of $2.2 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Payables soared 456.7% in 2024, then plunged 92.61% in 2026.
• Over 5 years, Payables stood at $2.4 million in 2022, then plunged by 30.47% to $1.7 million in 2023, then soared by 63.17% to $2.7 million in 2024, then sank by 61.54% to $1.0 million in 2025, then tumbled by 41.02% to $614000.0 in 2026.
• According to Business Quant data, Payables over the past three periods registered $614000.0, $261000.0, and $1.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.